Info

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises three products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride) and Aldurazyme (laronidase). As on December 31, 2007, BioMarin was conducting clinical trials on several product candidates for the treatment of genetic diseases, including PEG-PAL, formerly referred to as Phenylase (phenylalanine ammonia lyase), an enzyme substitution therapy for the treatment of phenylketonurics who are not responsive to Kuvan. On January 3, 2008, the Company purchased its previously leased facility in Novato, California. On December 18, 2007, BioMarin announced that it re-acquired the Canadian rights for BH4, including Kuvan, from Merck Serono, a division of Merck KGaA.(Source: 10-K)